Assembly Capital Surpluse from 2010 to 2024
| ASMB Stock | USD 16.30 1.10 7.24% |
Capital Surpluse | First Reported 2011-06-30 | Previous Quarter 807.9 M | Current Value 814.3 M | Quarterly Volatility 265.1 M |
Check Assembly Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Assembly Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 251.4 K, Interest Expense of 544.1 K or Selling General Administrative of 17.7 M, as well as many indicators such as Price To Sales Ratio of 6.87, Dividend Yield of 0.0 or PTB Ratio of 1.04. Assembly financial statements analysis is a perfect complement when working with Assembly Biosciences Valuation or Volatility modules.
Assembly | Capital Surpluse |
Latest Assembly Biosciences' Capital Surpluse Growth Pattern
Below is the plot of the Capital Surpluse of Assembly Biosciences over the last few years. It is Assembly Biosciences' Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Assembly Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Capital Surpluse | 10 Years Trend |
|
Capital Surpluse |
| Timeline |
Assembly Capital Surpluse Regression Statistics
| Arithmetic Mean | 473,959,359 | |
| Geometric Mean | 351,743,774 | |
| Coefficient Of Variation | 69.10 | |
| Mean Deviation | 294,777,376 | |
| Median | 364,528,037 | |
| Standard Deviation | 327,485,906 | |
| Sample Variance | 107247T | |
| Range | 873.5M | |
| R-Value | 0.98 | |
| Mean Square Error | 5360.6T | |
| R-Squared | 0.95 | |
| Slope | 71,508,502 | |
| Total Sum of Squares | 1501458.3T |
Assembly Capital Surpluse History
About Assembly Biosciences Financial Statements
Assembly Biosciences stakeholders use historical fundamental indicators, such as Assembly Biosciences' Capital Surpluse, to determine how well the company is positioned to perform in the future. Although Assembly Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Assembly Biosciences' assets and liabilities are reflected in the revenues and expenses on Assembly Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Assembly Biosciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Capital Surpluse | 929.1 M | 975.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Assembly Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Assembly Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Assembly Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Assembly Biosciences Stock:Check out the analysis of Assembly Biosciences Correlation against competitors. For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assembly Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.89) | Revenue Per Share 4.125 | Quarterly Revenue Growth (1.00) | Return On Assets (0.35) | Return On Equity (1.02) |
The market value of Assembly Biosciences is measured differently than its book value, which is the value of Assembly that is recorded on the company's balance sheet. Investors also form their own opinion of Assembly Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Assembly Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assembly Biosciences' market value can be influenced by many factors that don't directly affect Assembly Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Assembly Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assembly Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.